Veeva Systems Inc. $VEEV Shares Sold by Perpetual Ltd

Perpetual Ltd decreased its position in Veeva Systems Inc. (NYSE:VEEV) by 34.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,593 shares of the technology company’s stock after selling 6,199 shares during the quarter. Perpetual Ltd’s holdings in Veeva Systems were worth $3,454,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of VEEV. Sigma Planning Corp boosted its position in shares of Veeva Systems by 1.2% during the 2nd quarter. Sigma Planning Corp now owns 3,328 shares of the technology company’s stock valued at $958,000 after purchasing an additional 39 shares in the last quarter. Keybank National Association OH lifted its stake in Veeva Systems by 1.4% during the second quarter. Keybank National Association OH now owns 3,088 shares of the technology company’s stock valued at $889,000 after purchasing an additional 42 shares during the last quarter. Facet Wealth Inc. boosted its holdings in Veeva Systems by 3.3% during the second quarter. Facet Wealth Inc. now owns 1,342 shares of the technology company’s stock worth $381,000 after buying an additional 43 shares in the last quarter. Triangle Securities Wealth Management boosted its holdings in Veeva Systems by 0.8% during the second quarter. Triangle Securities Wealth Management now owns 5,782 shares of the technology company’s stock worth $1,665,000 after buying an additional 45 shares in the last quarter. Finally, Emerald Advisers LLC grew its position in Veeva Systems by 1.8% in the second quarter. Emerald Advisers LLC now owns 2,679 shares of the technology company’s stock worth $771,000 after buying an additional 47 shares during the last quarter. 88.20% of the stock is owned by institutional investors and hedge funds.

Veeva Systems Trading Up 1.8%

Shares of NYSE VEEV opened at $222.11 on Friday. Veeva Systems Inc. has a one year low of $201.54 and a one year high of $310.50. The business has a 50-day moving average price of $265.47 and a two-hundred day moving average price of $276.86. The firm has a market capitalization of $36.51 billion, a PE ratio of 43.21, a PEG ratio of 1.64 and a beta of 1.05.

Veeva Systems (NYSE:VEEV) last posted its quarterly earnings results on Thursday, November 20th. The technology company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.95 by $0.09. Veeva Systems had a net margin of 27.93% and a return on equity of 13.68%. The business had revenue of $0.81 million during the quarter, compared to analyst estimates of $792.37 million. During the same period in the prior year, the firm earned $1.75 earnings per share. The firm’s revenue was up 16.0% compared to the same quarter last year. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS and its Q4 2026 guidance at 1.920-1.920 EPS. Research analysts anticipate that Veeva Systems Inc. will post 4.35 EPS for the current year.

Wall Street Analysts Forecast Growth

VEEV has been the subject of several research reports. Stifel Nicolaus raised their price objective on Veeva Systems from $295.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. Mizuho upped their target price on Veeva Systems from $295.00 to $325.00 and gave the company an “outperform” rating in a report on Friday, August 29th. BTIG Research reissued a “buy” rating and issued a $340.00 price target on shares of Veeva Systems in a research note on Friday, November 21st. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Veeva Systems in a research note on Monday, December 15th. Finally, Evercore ISI lifted their target price on shares of Veeva Systems from $285.00 to $295.00 and gave the stock an “in-line” rating in a research report on Thursday, August 28th. Eighteen equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Veeva Systems currently has an average rating of “Moderate Buy” and a consensus target price of $307.42.

Insider Transactions at Veeva Systems

In related news, SVP Jonathan Faddis sold 14,595 shares of the stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $300.00, for a total transaction of $4,378,500.00. Following the completion of the sale, the senior vice president directly owned 8,588 shares in the company, valued at approximately $2,576,400. This trade represents a 62.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of Veeva Systems stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $306.62, for a total value of $1,839,720.00. Following the sale, the insider directly owned 25,325 shares of the company’s stock, valued at approximately $7,765,151.50. The trade was a 19.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 24,665 shares of company stock valued at $7,438,000. 10.30% of the stock is owned by insiders.

Veeva Systems Company Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.